Covid Vaccine Side Effects and Covid Infection after Vaccination- A Cross Sectional Study in Hubballi, Karnataka

Kashavva B  Andanigoudar; Dattatraya D  Bant; Shalini H; Oshin U

doi:10.5455/njcm.20211216122011

Authors

Kashavva B Andanigoudar Department of Community Medicine, KIMS, Hubballi
Dattatraya D Bant Department of Community Medicine, KIMS, Hubballi
Shalini H Department of Community Medicine, JJMMC, Davangere
Oshin U Department of Community Medicine, KIMS, Hubballi

DOI:

https://doi.org/10.5455/njcm.20211216122011

Keywords:

side effects, Covid-19 vaccines, co-morbidities, re-infection, breakthrough infection

Abstract

Introduction: Vaccination against Covid-19 has become the promising strategy in controlling rise in Covid cases. Covishield and Covaxin were the two vaccines initially available in India which have been administered to all those >18years of age. These vaccines exhibit a spectrum of side effects, which may affect vaccination rates. The study was conducted to estimate the frequency of side effects of Covid vaccines in India and their relationship with co-morbidities and prior Covid-19 infection.

Methodology: A cross sectional questionnaire-based online survey was conducted for duration of one month among 1800 participants who had received at least one dose of Covid vaccine at KIMS Hospital, Hubballi, Karnataka, selected using systematic random sampling and information about vaccination, comorbidities and covid infection after vaccination was collected.

Results: The most common side effects were fever, headache and generalised body ache. The prevalence of infection after complete vaccination with Covishield (4.45%) was higher than Covaxin (1.08%) and difference was statistically significant. The prevalence of side effects and Covid-19 infection after vaccination did not vary with co-morbidities.

Conclusion: The side effects reported were not serious and the prevalence was similar in both the vaccines. The prevalence of infection still remains high after vaccination; hence Covid Appropriate Behaviour should be continued.

References

Li Q. An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province, 2019−2020. China CDC Weekly. 2020;2(5):79-80.

Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W et al. A Novel Coro-navirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019−2020. China CDC Weekly. 2020;2(4):61-62.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020;382(8):727-733.

WHO Director-General's opening remarks at the media brief-ing on COVID-19 - 23 October 2020 [Internet]. Who.int. 2022 [cited 25 June 2021]. Available from: https://www.who.int/ director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---23-october-2020

WHO Coronavirus (COVID-19) Dashboard [Internet]. Covid19. who.int. 2022 [cited 23 August 2021]. Available from: https:// covid19.who.int/

Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine [Internet]. Icmr.gov.in. 2022 [cited 18 June 2021]. Available from: https://www.icmr.gov.in/pdf/press_realease_ files/HFW_DCGI_energency_use_authorisation_03012021_2.pdf

Cumulative Coverage Report of COVID-19 Vaccination [Inter-net]. MyGov.in. 2021 [cited 3 July 2021]. Available from: https://www.mygov.in/covid-19

10. Precautions and Contraindications for COVID-19 Vaccines [Internet]. Mohfw.gov.in. 2022 [cited 23 June 2021]. Available from: https://www.mohfw.gov.in/pdf/LetterfromAddlSecy MoHFWregContraindicationsandFactsheetforCOVID19vacci-nes.PDF

Solís Arce J, Warren S, Meriggi N, Scacco A, McMurry N, Voors M et al. COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries. Nature Medicine. 2021; 27(8): 1385-1394.

CDC. COVID‐19 Vaccine Effectiveness Research. 2021 [cited 23 June 2021]. Available from: https://www.cdc.gov/vaccines/ covid-19/effectivenessresearch/ protocols.html

Kaur R, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P et al. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. Indian Journal of Clinical Biochemistry. 2021;36(4):427-439.

Jęśkowiak I, Wiatrak B, Grosman-Dziewiszek P, Szeląg A. The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19. Vaccines. 2021;9(5):502.

Alghamdi A, Alkazemi A, Alissa A, Alghamdi I, Alwarafi G, Waggas H. Adverse Events Following AstraZeneca COVID-19 Vaccine in Saudi Arabia: A Cross-Sectional Study among Healthcare and Non-healthcare Workers. Intervirology. 2021.

Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Human Vaccines & Immunotherapeutics. 2021:1-8.

Zare H, Rezapour H, Mahmoodzadeh S, Fereidouni M. Preva-lence of COVID-19 vaccines (Sputnik V, AZD-1222, and Co-vaxin) side effects among healthcare workers in Birjand city, Iran. International Immunopharmacology. 2021;101:108351.

Dash G, Subhadra S, Turuk J, Parai D, Rath S, Sabat J et al. Breakthrough SARS‐CoV‐2 infections among BBV‐152 (COVAXIN®) and AZD1222 (COVISHIELD TM ) recipients: Report from the eastern state of India. Journal of Medical Virology. 2021;.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021;384(5):403-416.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020; 383(27): 2603-2615.

Bagchi S, Mak J, Li Q, Sheriff E, Mungai E, Anttila A et al. Rates of COVID-19 Among Residents and Staff Members in Nursing Homes — United States, May 25–November 22, 2020. MMWR Morbidity and Mortality Weekly Report. 2021;70(2):52-55.